Regenxbio Reports Positive Results from Phase I/II...
Category : Clinical Trial Update 5 September 2024Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX-121 to treat patients...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX-121 to treat patients...
Overview Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned...
Sanofi’s HERCULES phase 3 study of tolebrutinib to treat non-relapsing secondary progressive M...
Nxera Pharma to get US$ 35 mn from Neurocrine for successful completion of phase 2 trial with NBI-11...
Bayer initiates patient enrolment in phase III SOHO-02 trial of BAY 2927088 in non-small cell lung c...